Edding Genor Group Holdings Limited (06998)
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in clinical development for autoimmune diseases; and
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
